AC, MD (NSW), PhD (Syd.), FRACP, FAFPHM, FAHMS
Distinguished Laureate Professor, University of Newcastle, and Director, Centre of Research Excellence in Digestive Health, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
Professor Nicholas J. Talley, AC, MD (NSW), PhD (Syd.), FRACP, FAFPHM, FAHMS is a distinguished physician scientist and gastroenterologist, with a special interest in functional and inflammatory gastrointestinal diseases. He is currently Distinguished Laureate Professor of Medicine at the University of Newcastle; Nick has protected time for research and clinical practice as part of this appointment. He is a Past President of the Royal Australasian College of Physicians, a past Chair of the Council of Presidents of Medical Colleges, former committee member of the Australian Academy of Health and Medical Sciences, a former member of the NHMRC Research Committee and MBS taskforce, and is the Editor-in-Chief of the Medical Journal of Australia. Nick has an outstanding highly cited academic track-record with over 1000 publications. He is CIA on a NHMRC CRE in Digestive Health and is a chief investigator on several other successfully completed NHMRC and NIH grants, and has attracted funding worth more than AUD$15 million dollars in the last 5 years. Nick has won several prestigious research awards including the Distinguished Research Prize from the Gastroenterological Society of Australia (GESA), Newcastle Innovation Excellence in Innovation Award, the NSW Excellence in Biological Sciences (Cell and Molecular, Medical and Veterinary and Genetics), 2018 NSW Scientist of the Year, and– Bruce Shepard Medal from Research Australia, Mayo Clinic Distinguished Alumnus 2020, PlosOne most cited in Gastroenterology 2020 and the UNSW Alumni Award 2021. He is invited to deliver lectures and present his research around the world, and is considered an international authority in the field.
Dr Nicholas J. Talley reports personal fees from Allakos, from Aviro Health, from Antara Life Sciences, from Arlyx from Bayer, from Danone, from Planet Innovation, from Takeda, from Viscera Labs, from twoXAR, from Viscera Labs, from Dr Falk Pharma , from Censa, from Cadila Pharmaceuticals , from Progenity Inc, from Sanofi-aventis, from Glutagen, from ARENA Pharmaceuticals , from IsoThrive, from BluMaiden, from RosePharma, from Intrinsic Medicine. from HVN National Science Challenge, non-financial support from HVN National Science Challenge NZ, outside the submitted work; In addition, NJT has a patent Biomarkers of IBS licensed (#12735358.9 -1405/2710383 and (#12735358.9 -1405/2710384), a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to Mayo/Talley, a patent Nestec European Patent licensed, and a patent Singapore Provisional Patent NTU Ref: TD/129/17 “Microbiota Modulation Of BDNF Tissue Repair Pathway” issued and copyright Nepean Dyspepsia Index (NDI) 1998, “Diagnostic marker for functional gastrointestinal disorders” Australian Provisional Patent Application 2021901692, and Editorial: Medical Journal of Australia (Editor in Chief), Up to Date (Section Editor), Precision and Future Medicine, Sungkyunkwan University School of Medicine, South Korea, Med (Journal of Cell Press). NJT participates Committees: OzSAGE, Australian Medical Council (AMC) Council Member (2016-2019), MBS Review Taskforce (2016-2020), NHMRC Principal Committee, Research Committee (2016-2021), Asia Pacific Association of Medical Journal Editors (APAME) (current), GESA Board Member (2017-2019). NJT Misc: Avant Foundation (judging of research grants) (2019). NJT community and patient advocacy groups: Advisory Board, IFFGD (International Foundation for Functional GI Disorders). NJT acknowledges funding from the National Health and Medical Research Council (NHMRC) for the Centre for Research Excellence in Digestive Health. NJT holds an NHMRC Investigator grant.